Over the past decade, CDISC Standards have been widely accepted and implemented in clinical research. The FDA’s final “Guidance for Industry on electronic submission” mandates that submission data conform to CDISC standards such as SDTM, ADaM and SEND. This presentation will discuss how life sciences organizations can use Standards metadata to manage the regulatory compliance process. It will introduce how standards metadata management not only ensures regulatory compliance, but also supports process efficiency in clinical trial artefacts (e.g., protocol, CDASH, SDMT and ADaM) development and standards governance, and enables efficient communication between organizational units.
It will also introduce metadata management system and discuss how metadata management system will create, store, govern and manage standards. It will also show how standards metadata management system interacts with ETL system and dictates standards-driven clinical artefacts development.
First, let’s us take a look at current status in electronic submission.
And, if we look at CDISC submission, FDA is also getting more of CDISC data.
The FDA Guidance document will be binding rather than recommendation.
According to Ron Fitzmartin, it is Yes. FDA CSS 2015 Ron Fitzmartin said it.
Metadata Management System will manage standards metadata
ETL system will feed this standards metadata to drive automated clinical artefacts development
Stan
These Clinical Artefacts are just examples. These could go beyond to TFL generation
Some of ETL Systems
Three Standards metadata -
As you see there are three different data structures, source, target and transformation metadata